FIG. 1B




% BTK Inhibition
100
80
60
40
20
0
Desired Inhibition Range
0
5
10
15
20
25
Time hr
1000
500
0
PK Exposure ng/ml

FIG. 1A


OFF-TARGET SITE
COVALENT BINDING REGION
COVALENT BINDING SITE
TARGET SITE
NON-COVALENT BINDING REGION



Higher Dose
Continue at Initial Dose
No response; escalate to higher dose
Response
Initial Dose

FIG. 2

FIG. 3B



% Maximum Aggregation
150
100
50
0
5 µM TRAP
10 µM ADP
1.5 mg/mL Ristocetin
5 µM U46619
5 µg/mL Collagen
2.5 µg/mL Collagen

FIG. 3A



% Maximum Aggregation
150
100
50
0
5 µM TRAP
10 µM ADP
1.5 mg/mL Ristocetin
5 µM U46619
5 µg/mL Collagen
2.5 µg/mL Collagen

FIG. 4



% Maximum Aggregation
150
100
50
0
5 µM TRAP
10 µM ADP
1.5 mg/mL Rotocetin
5 µM U46619
5 µg/mL Collagen
2.5 µg/mL Collagen

FIG. 5



PRN1008 Dose (mg/day)
800
700
600
500
400
300
200
100
0
Platelet Count (x 10^9/L)
340
320
300
280
260
240
220
200
180
160
140
120
100
80
60
40
20
0
-6
8
22
36
50
64
78
92
106
120
134
148
162
176
190
204
218
232
246
260
274
288
302
316
330
Study Day

FIG. 6



Responders
Non-responders
Low Starting Dose (QD dosing) n=10
Platelet Count x 10^9/L
Days

FIG. 7



High Starting Dose (eID dosing) n=21
Responders
Non-responders
Platelet Count x 10^9/L
Days

FIG. 8



39%
40%
40%
38%
0%
20%
40%
60%
Platelet Response
Primary Response (N=31)
Heavily Pretreated (≥4 Prior Therapies) (n=25)
PRN1008 Monotherapy (n=10)
PRN1008 + Concomitant Therapy (n=21)

FIG. 9




Responded within 4 weeks
Responders
Non-responders
Starting Dose 400 mg bid (n = 32)
Platelet Counts (x 10^9/L)
Days

FIG. 10


Primary Response (N = 47)
Completed ≥12 Wk Rilzabrutinib (n = 36)
Baseline Platelets ≤15K (n = 25)
Heavily Pretreated (≥4 Prior Therapies) (n = 38)
Rilzabrutinib Monotherapy (n = 16)
Rilzabrutinib + Concomitant Therapy (n = 31)
43%
50%
40%
40%
44%
42%
0%
25%
50%
75%
100%
Platelet Response